Advancis Pharmaceutical Announces Promotion of Robert C. Low to Chief Financial Officer
23 Oktober 2006 - 11:43PM
PR Newswire (US)
Former Acting Financial Chief Named Advancis CFO GERMANTOWN, Md.,
Oct. 23 /PRNewswire-FirstCall/ -- Advancis Pharmaceutical
Corporation (NASDAQ:AVNC), a pharmaceutical company focused on
developing and commercializing novel anti-infective products, today
announced the promotion of Robert C. Low to Vice President, Finance
and Chief Financial Officer (CFO), effective immediately. Mr. Low
previously served as Vice President, Finance and Acting CFO, and
had joined Advancis in August 2003 as Corporate Controller. "Bob
has been a critical part of our management team since joining the
Company and has been instrumental in developing our financial
reporting and regulatory compliance initiatives. His significant
experience and technical expertise position him extremely well to
formally assume the additional responsibilities of Advancis Chief
Financial Officer," said Edward M. Rudnic, Ph.D., president and CEO
of Advancis. "Bob has demonstrated his leadership and management
abilities throughout his transitional period as acting CFO, and we
are happy to recognize his contributions to Advancis through this
promotion." Mr. Low joined Advancis in August 2003 as corporate
controller and has been responsible for the Company's accounting,
tax, financial reporting, and internal controls since that time.
Prior to joining Advancis, he was senior vice president and
corporate controller for American Medical Laboratories, Inc. prior
to its acquisition by Quest Diagnostics, Inc. Mr. Low has an
extensive background in public accounting, auditing, and in senior
accounting positions with publicly-traded companies. He is also a
Certified Public Accountant. ABOUT ADVANCIS PHARMACEUTICAL:
Advancis Pharmaceutical Corporation (NASDAQ:AVNC) is a
pharmaceutical company focused on the development and
commercialization of anti-infective drug products that fulfill
substantial unmet medical needs in the treatment of infectious
disease. The Company is developing a portfolio of anti-infective
drugs based on its novel biological finding that bacteria exposed
to antibiotics in frontloaded staccato bursts, or "pulses," are
killed more efficiently and effectively than those under standard
treatment regimens. Based on this finding, Advancis has developed a
proprietary, once-a-day pulsatile delivery technology called
PULSYS. By examining the resistance patterns of bacteria and
applying its delivery technologies, Advancis has the potential to
redefine infectious disease therapy and significantly improve drug
efficacy, shorten length of therapy, and reduce drug resistance
versus currently available antibacterial products. For more on
Advancis, please visit http://www.advancispharm.com/. This
announcement contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
These statements are based on Advancis' current expectations and
assumptions. These statements are not guarantees of future
performance and are subject to a number of risks and uncertainties
that would cause actual results to differ materially from those
anticipated. The words, "believe," "expect," "intend,"
"anticipate," "plan," "hope," and variations of such words, and
similar expressions identify forward-looking statements, but their
absence does not mean that the statement is not forward-looking.
Statements in this announcement that are forward-looking include,
but are not limited to, statements about the Company's future
development plans, clinical trials, and financial results. The
actual results realized by Advancis could differ materially from
these forward-looking statements, depending in particular upon the
risks and uncertainties described in the Company's filings with the
Securities and Exchange Commission. These include, without
limitation, risks and uncertainties relating to the Company's
financial results and the ability of the Company to (1) reach
profitability, (2) prove that the preliminary findings for its
product candidates are valid, (3) receive required regulatory
approvals, (4) successfully conduct clinical trials in a timely
manner, (5) establish its competitive position for its products,
(6) develop and commercialize products that are superior to
existing or newly developed competitor products, (7) develop
products without any defects, (8) have sufficient capital resources
to fund its operations, (9) protect its intellectual property
rights and patents, (10) implement its sales and marketing
strategy, (11) successfully attract and retain collaborative
partners, (12) successfully develop, commercialize, and receive
market acceptance of its Keflex products, and (13) retain its
senior management and other personnel. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of today's date.
Advancis undertakes no obligation to update or revise the
information in this announcement, whether as a result of new
information, future events or circumstances or otherwise.
DATASOURCE: Advancis Pharmaceutical Corporation CONTACT: Bob
Bannon, Vice President, Investor Relations & Corporate
Communications of Advancis Pharmaceutical Corporation,
+1-301-944-6710, or Web site: http://www.advancispharm.com/
Copyright
Advancis (NASDAQ:AVNC)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
Advancis (NASDAQ:AVNC)
Historical Stock Chart
Von Jun 2023 bis Jun 2024